- |||||||||| S-pindolol (ACM-001) / Actimed Therap, Entyvio (vedolizumab) / Takeda
The development of a gut-specific immune response to an oral antigen is dependent on α4β7 mediated lymphocyte trafficking (Exhibit Hall; P162) - Apr 8, 2022 - Abstract #IMMUNOLOGY2022IMMUNOLOGY_1620;
α4β7-specific inhibitor, MT-102, effectively diminished the mucosal antibody response to an orally delivered Ag in mice. These results are consistent with what has been reported clinically in vedolizumab-treated subjects and thus establishes that potent small molecule inhibitors of α4β7 can replicate the pharmacology of an antibody.
- |||||||||| S-pindolol (ACM-001) / Actimed Therap
Preclinical, Journal: MT-102 prevents tissue wasting and improves survival in a rat model of severe cancer cachexia. (Pubmed Central) - Jul 8, 2021
These results are consistent with what has been reported clinically in vedolizumab-treated subjects and thus establishes that potent small molecule inhibitors of α4β7 can replicate the pharmacology of an antibody. The present study shows that 3 mg kg MT-102 reduces catabolism, while inducing anabolism in skeletal muscle leading to an improved survival.
|
